416 related articles for article (PubMed ID: 36632988)
1. Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes.
Zajac KK; Malla S; Babu RJ; Raman D; Tiwari AK
Cancer Rep (Hoboken); 2023 Sep; 6 Suppl 1(Suppl 1):e1779. PubMed ID: 36632988
[TBL] [Abstract][Full Text] [Related]
2. Immune microenvironment of triple-negative breast cancer in African-American and Caucasian women.
O'Meara T; Safonov A; Casadevall D; Qing T; Silber A; Killelea B; Hatzis C; Pusztai L
Breast Cancer Res Treat; 2019 May; 175(1):247-259. PubMed ID: 30725384
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
Front Immunol; 2019; 10():757. PubMed ID: 31031757
[TBL] [Abstract][Full Text] [Related]
4. Quantitative assessment of the immune microenvironment in African American Triple Negative Breast Cancer: a case-control study.
Yaghoobi V; Moutafi M; Aung TN; Pelekanou V; Yaghoubi S; Blenman K; Ibrahim E; Vathiotis IA; Shafi S; Sharma A; O'Meara T; Fernandez AI; Pusztai L; Rimm DL
Breast Cancer Res; 2021 Dec; 23(1):113. PubMed ID: 34906209
[TBL] [Abstract][Full Text] [Related]
5. Regulatory T cells: Their role in triple-negative breast cancer progression and metastasis.
Malla RR; Vasudevaraju P; Vempati RK; Rakshmitha M; Merchant N; Nagaraju GP
Cancer; 2022 Mar; 128(6):1171-1183. PubMed ID: 34990009
[TBL] [Abstract][Full Text] [Related]
6. Racial Disparities in Triple Negative Breast Cancer: A Review of the Role of Biologic and Non-biologic Factors.
Prakash O; Hossain F; Danos D; Lassak A; Scribner R; Miele L
Front Public Health; 2020; 8():576964. PubMed ID: 33415093
[TBL] [Abstract][Full Text] [Related]
7. The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression.
Kim G; Pastoriza JM; Condeelis JS; Sparano JA; Filippou PS; Karagiannis GS; Oktay MH
Front Oncol; 2020; 10():1022. PubMed ID: 32714862
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment.
Adinew GM; Taka E; Mochona B; Badisa RB; Mazzio EA; Elhag R; Soliman KFA
Nutrients; 2021 Dec; 14(1):. PubMed ID: 35010954
[TBL] [Abstract][Full Text] [Related]
9. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
[TBL] [Abstract][Full Text] [Related]
10. Racial Disparity and Triple-Negative Breast Cancer in African-American Women: A Multifaceted Affair between Obesity, Biology, and Socioeconomic Determinants.
Siddharth S; Sharma D
Cancers (Basel); 2018 Dec; 10(12):. PubMed ID: 30558195
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the tumor and obese microenvironment to triple negative breast cancer.
Kaul K; Misri S; Ramaswamy B; Ganju RK
Cancer Lett; 2021 Jul; 509():115-120. PubMed ID: 33798632
[TBL] [Abstract][Full Text] [Related]
12. Outcome disparities in African American women with triple negative breast cancer: a comparison of epidemiological and molecular factors between African American and Caucasian women with triple negative breast cancer.
Sturtz LA; Melley J; Mamula K; Shriver CD; Ellsworth RE
BMC Cancer; 2014 Feb; 14():62. PubMed ID: 24495414
[TBL] [Abstract][Full Text] [Related]
13. IRE1α Disruption in Triple-Negative Breast Cancer Cooperates with Antiangiogenic Therapy by Reversing ER Stress Adaptation and Remodeling the Tumor Microenvironment.
Harnoss JM; Le Thomas A; Reichelt M; Guttman O; Wu TD; Marsters SA; Shemorry A; Lawrence DA; Kan D; Segal E; Merchant M; Totpal K; Crocker LM; Mesh K; Dohse M; Solon M; Modrusan Z; Rudolph J; Koeppen H; Walter P; Ashkenazi A
Cancer Res; 2020 Jun; 80(11):2368-2379. PubMed ID: 32265225
[TBL] [Abstract][Full Text] [Related]
14. Targeting molecular cross-talk between tumor cells and tumor associated macrophage as therapeutic strategy in triple negative breast cancer.
Shettigar A; Salunke R; Modi D; Mukherjee N
Int Immunopharmacol; 2023 Jun; 119():110250. PubMed ID: 37163922
[TBL] [Abstract][Full Text] [Related]
15. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.
Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR
Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092
[TBL] [Abstract][Full Text] [Related]
16. CXCL14 Attenuates Triple-Negative Breast Cancer Progression by Regulating Immune Profiles of the Tumor Microenvironment in a T Cell-Dependent Manner.
Gibbs C; So JY; Ahad A; Michalowski AM; Son DS; Li Y
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012586
[TBL] [Abstract][Full Text] [Related]
17. Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment.
Wu TN; Chen HM; Shyur LF
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948368
[TBL] [Abstract][Full Text] [Related]
18. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
[TBL] [Abstract][Full Text] [Related]
19. Concomitant activation of GLI1 and Notch1 contributes to racial disparity of human triple negative breast cancer progression.
Siddharth S; Parida S; Muniraj N; Hercules S; Lim D; Nagalingam A; Wang C; Gyorffy B; Daniel JM; Sharma D
Elife; 2021 Dec; 10():. PubMed ID: 34889737
[TBL] [Abstract][Full Text] [Related]
20. Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated With an Immunosuppressive Tumor Microenvironment.
Semba T; Wang X; Xie X; Cohen EN; Reuben JM; Dalby KN; Long JP; Phi LTH; Tripathy D; Ueno NT
J Natl Cancer Inst; 2022 Jan; 114(1):97-108. PubMed ID: 34250544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
